Anavex Life Sciences Corp (AVXL)

[falconer66a]

Against Pain — Another Big Market

Does this article speak to the potential of A-1066?
https://www.frontiersin.org/articles/10.3389/fphar.2019.00222/full

In a quick internet search I could find no specific info on the mechanism of action of the molecule in the article. But in its analgesic effects it involves the sigma-1 receptor (as described in the journal article).

To treat or prevent the involved pain in rats, the molecule, MR-309, was injected, not consumed in food or drinking water (unlike the Anavex sigma-1 receptor agonists in the murine studies I’ve read). In this study, the molecule produced favorable analgesic outcomes.

Very likely, then, Anavex-1066 will, too. The Anavex pipeline page indicates that Anavex-1066 is to be at some time clinically tested against various forms of pain.

If it is administered like the other Anavex molecules, it will be in drinking water. However, it might well be injected into patients immediately after spinal cord injuries, to maximize its analgesic outcomes.

As with the other indications for the Anavex drugs, big market; big need. Spinal cord injuries tend to be recalcitrant. Being able to prevent and/or suppress the many pains from spinal cord injuries would be a major medical development.

Lastly, the company isn’t putting pain treatments on their pipeline page without some indication that their drug will have this application. Certainly, they’ve tested it on their own lab rats, know that it works for them. Next, in humans....